Saul A. Rosenberg

George Washington University — United States

Medicine · Health Sciences

64h-index14.3kcitations178works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(137), Lung Cancer Treatments and Mutations(53), Viral-associated cancers and disorders(40), Chronic Lymphocytic Leukemia Research(36), CNS Lymphoma Diagnosis and Treatment(31)

Publications178 total

Unburied polytetrafluoroethylene scleral suture erosions and failure of pericardial graft revision
American Journal of Ophthalmology Case Reports·2024Open Access
RWD161 Therapeutic Drug Monitoring (TDM) of Infliximab Is Associated with Lower Biologic Switch & Expenditures Compared to No-TDM Cohort of IBD Patients Based on 12 to 48-Month Real-World Outcomes from a US Community GI Practice
Value in Health·2024Open Access
Long-Term Outcomes of Patients With Early Stage Nonbulky Hodgkin Lymphoma Treated With Combined Modality Therapy in the Stanford V Trials (the G4 and G5 Studies)
International Journal of Radiation Oncology*Biology*Physics·2020· 3 cited
Long-term outcomes of patients with unfavorable stage I–II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation
Leukemia & lymphoma/Leukemia and lymphoma·2020· 4 cited
Sequential Radiotherapy and Chemotherapy in the Treatment of Hodgkin's Disease
Annals of Internal Medicine·2020
No Utility of Routine Laboratory Testing during Surveillance in Detecting Relapse in Patients with Classic Hodgkin Lymphoma in First Remission
Blood·2018
The Outcomes of Patients with Unfavorable Stage I-II Classic Hodgkin Lymphoma Treated with Stanford V Chemotherapy and Limited Irradiation
International Journal of Radiation Oncology*Biology*Physics·2018Open Access
Prognostic Factors and Patterns of Failure in Advanced Stage Hodgkin Lymphoma Treated with Stanford V and Radiation Therapy
International Journal of Radiation Oncology*Biology*Physics·2018
Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy
Radiotherapy and Oncology·2018· 2 cited
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
eScholarship (California Digital Library)·2015Open Access
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
Mayo Clinic Proceedings·2015· 144 citedOpen Access
The Paris Conference “La Radiothérapie de la Maladie de Hodgkin”: A First Step in the Cure of Hodgkin Disease
International Journal of Radiation Oncology*Biology*Physics·2015· 1 cited
Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma
Annals of Oncology·2014· 38 cited
Treatment of Hodgkin Lymphoma: A 50-Year Perspective
Journal of Clinical Oncology·2014· 155 citedOpen Access
Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma
American Journal of Clinical Oncology·2014· 6 citedOpen Access
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience
Blood·2013· 260 citedOpen Access
The Range of Cancers Treatable by Genetically Modified Cells
AACR Education book·2013
Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials
Journal of Clinical Oncology·2013· 96 citedOpen Access
Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial
Annals of Oncology·2012· 37 citedOpen Access
Outcome of Patients with Advanced Hodgkin Lymphoma Who Are Either Refractory to or Relapsed After Primary Therapy with the Stanford V Regimen
Blood·2010
page 1 of 9Next →

Frequent Co-authors

Henry S. Kaplan(21), Sandra J. Horning(9), Richard T. Hoppe(9), Eli Glatstein(6), Stephen E. Jones(4), Thomas V. Colby(4), R S Cox(3), Zvi Fuks(3), Ronald F. Dorfman(3), Ranjana H. Advani(3), Carol S. Portlock(3), Henry D. Diamond(2), Lloyd F. Craver(2), C. Norman Coleman(2), Marshall E. Kadin(2), Hun Kim(2), John G. Krikorian(2), Jerome S. Burke(2), F. Roy MacKintosh(2), Thomas C. Merigan(2)